Skip to main content
. 2016 Jan 31;7(10):11137–11150. doi: 10.18632/oncotarget.7097

Figure 5. Increased expression of the M2 cytokines IL-10 and CCL20 in the plasma of metastatic breast cancer patients and decrease of IL-10 levels by bevacizumab.

Figure 5

(A) Quantification of M1 cytokines TNFα, IL-12p70 and CCL2 in plasma of healthy donors and cancer patients before therapy start. (B) Quantification of M2 cytokines IL-10 and CCL20 in the plasma of the same healthy donors and cancer patients before therapy start. (C) Quantification of CD163, (D) ARG1 and (E) IL-10 mRNA expression variation in CD11b+ cells of cancer patient during therapy with paclitaxel ± bevacizumab using real time qPCR. (F) Quantification of IL-10 in the plasma of cancer patients during therapy with paclitaxel ± bevacizumab. Cytokines were measured by ELISA. All data are represented as mean +/− SD.